A share price of ProQR Therapeutics N.V [PRQR] is currently trading at $1.72, down -2.27%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PRQR shares have gain 10.97% over the last week, with a monthly amount glided 27.41%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Evercore ISI started tracking the stock with Outperform rating on April 29, 2025, and set its price target to $5. On March 10, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $4 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $15 on January 10, 2025. Raymond James upgraded its rating to a Strong Buy and raised its price target to $14 on October 29, 2024. Chardan Capital Markets upgraded its rating to Buy for this stock on November 08, 2023, but kept the price target unchanged to $2. In a note dated March 30, 2023, JMP Securities upgraded an Mkt Outperform rating on this stock and boosted its target price from $1.50 to $5.
ProQR Therapeutics N.V experienced fluctuations in its stock price throughout the past year between $1.07 and $4.62. Currently, Wall Street analysts expect the stock to reach $3.63 within the next 12 months. ProQR Therapeutics N.V [NASDAQ: PRQR] shares were valued at $1.72 at the most recent close of the market. An investor can expect a potential return of 111.05% based on the average PRQR price forecast.
Analyzing the PRQR fundamentals
Trailing Twelve Months sales for ProQR Therapeutics N.V [NASDAQ:PRQR] were 20.36M which represents -1.53% decline. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -1.76%, Pretax Profit Margin comes in at -1.6%, and Net Profit Margin reading is -1.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.54 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for ProQR Therapeutics N.V [NASDAQ:PRQR] is 4.10. As well, the Quick Ratio is 4.10, while the Cash Ratio is 3.93. Considering the valuation of this stock, the price to sales ratio is 8.89, the price to book ratio is 2.13.
